Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both declined even as the rest of the market rose.Short-term price changes shouldn't have anything to do with an investment thesis for either stock. Still, investors sold shares in both for a reason. And there's a chance that the issue driving the decline is going to stick around, so let's see what's going on and determine how it might change your investing strategy.Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to treat type 2 diabetes. Novo's drugs Ozempic and Wegovy are household names already, and Lilly's Mounjaro and Zepbound are close behind.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool